MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in...
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will...
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs...
Newly uncovered DEA agreements confirm what MMJ BioPharma Cultivation has argued for years - that the agency's own rules make...
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust...
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in...
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass.,...
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis...
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing...
Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including...
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms...
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast...
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine...
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in...